Vonda buys IFN 25.61: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations
PHILADELPHIA, May 27, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx ... in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C ... ...
40 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home